Bright Minds Biosciences to Present at AES 2024 Meeting

Ticker: DRUG · Form: 6-K · Filed: Nov 21, 2024 · CIK: 1827401

Bright Minds Biosciences INC. 6-K Filing Summary
FieldDetail
CompanyBright Minds Biosciences INC. (DRUG)
Form Type6-K
Filed DateNov 21, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: conference-presentation, biotech, data-release

Related Tickers: BMBS

TL;DR

BMBS presenting epilepsy data at AES 2024 meeting. Good sign for pipeline.

AI Summary

Bright Minds Biosciences Inc. announced on November 21, 2024, that it will present data at the American Epilepsy Society 2024 Annual Meeting. The company, located at 19 Vestry Street, New York, NY 10013, filed this Form 6-K report.

Why It Matters

Presenting data at a major industry conference like the American Epilepsy Society meeting can generate interest and potentially validate the company's research and development efforts.

Risk Assessment

Risk Level: low — This filing is a routine announcement of a presentation at a conference, with no immediate financial or operational changes disclosed.

Key Players & Entities

FAQ

What specific data will Bright Minds Biosciences present at the American Epilepsy Society 2024 Annual Meeting?

The filing does not specify the exact data to be presented, only that data will be presented.

When is the American Epilepsy Society 2024 Annual Meeting scheduled to take place?

The filing does not provide the dates for the American Epilepsy Society 2024 Annual Meeting.

Who is Ryan Cheung and what is his role at Bright Minds Biosciences Inc.?

Ryan Cheung is identified as 'Chief' and signed the report on behalf of Bright Minds Biosciences Inc.

What is the principal executive office address for Bright Minds Biosciences Inc.?

The principal executive office is located at 19 Vestry Street, New York, NY 10013.

What type of report is this Form 6-K filing?

This is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

Filing Stats: 174 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2024-11-21 11:30:03

Filing Documents

From the Filing

Bright Minds Biosciences Inc.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F [ X ] Form 40-F [ ] SUBMITTED HEREWITH Exhibits 99.1 News Release dated November 21, 2024 re: Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BRIGHT MINDS BIOSCIENCES INC. /s/ Ryan Cheung __________________________ Ryan Cheung Chief Financial Officer Date: November 21, 2024

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing